Recent positive Phase 3 results from the INTerpath-001 trial of Moderna and Merck’s personalized mRNA neoantigen vaccine intismeran autogene (mRNA-4157/V940) form the main driver of elevated trader sentiment on a timely BLA submission. The October 2026 data showed the vaccine plus Keytruda reduced melanoma recurrence or death risk by 42% and distant metastasis risk by 38% versus Keytruda alone in over 1,100 high-risk resected patients, marking the first late-stage success for this individualized mRNA approach. Companies are actively engaging regulators and preparing filings, with analysts projecting a 2027 launch. Full ESMO data presentation and any accelerated review signals represent key near-term catalysts that could further support or delay the timeline amid typical oncology review uncertainties.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · UpdatedView resolved

Beware of external links.
Beware of external links.
Frequently Asked Questions